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MiceAsthma therapies are effective in reducing inflammation but airway remodeling is poorly responsive to these
agents. New therapeutic options that have fewer side effects and reverse chronic changes in the lungs are
essential. Mesenchymal stem cells (MSCs) are promising for the development of novel therapies in regenerative
medicine. This study aimed to examine the efficacy ofMSCs on lung histopathology in amurinemodel of chronic
asthma. BALB/cmicewere divided into four groups: Group 1 (control group, n=6), Group 2 (ovalbumin induced
asthma only, n=10), Group 3 (ovalbumin induced asthma +MSCs, n=10), and Group 4 (MSCs only, n=10).
Histological findings (basement membrane, epithelium, subepithelial smooth muscle thickness, numbers of
goblet and mast cells) of the airways and MSC migration were evaluated by light, electron, and confocal
microscopes. In Group 3, all early histopathological changes except epithelial thickness and all of the chronic
changes were significantly ameliorated when compared with Group 2. Evaluation with confocal microscopy
showed that nonoteworthy amount ofMSCswere present in the lung tissues ofGroup4while significant amount
ofMSCs was detected in Group 3. SerumNO levels in Group 3, were significantly lower than Group 2. The results
of this study revealed that MSCs migrated to lung tissue and ameliorated bronchial asthma in murine model.
Further studies are needed to evaluate the efficacy of MSCs for the treatment of asthma.+90 232 4123649.
i@yahoo.com (F. Firinci).
ll rights reserved.© 2011 Elsevier B.V. All rights reserved.1. Introduction
Asthma is a chronic disease characterized by reversible airway
obstruction, airway inflammation and remodeling [1]. Current strate-
gies for the management of asthma focus on suppressing airway
inflammation [2]. Inhaled glucocorticoids are currently the mainstay of
asthma therapy although several side effects may arise when they are
used at high doses or for a prolonged time [3]. Airway remodeling
consists of progressive structural changes in the composition, content,
andorganizationof the cellular andmolecular constituentsof the airway
wall [4]. Although current asthma therapies are effective in reducing
inflammation, airway remodeling is poorly responsive to current
therapies, such as inhaled corticosteroids, antileukotrienes, and the-
ophylline [4,5]. For this reason, new therapeutic options are required.
Mesenchymal stem cells (MSCs) are emerging as a therapeutic
modality in various inflammatory diseases. MSCs have the potential to
differentiate into various connective tissue lineages including adiposetissue, marrow stroma, cartilage, tendon and bone [6]. Additionally,
studies during the last decade have suggested that MSCs may have
more plasticity and are able to differentiate into bronchial and
alveolar epithelium, vascular endothelium, and interstitial cell types
[7]. MSCs can be isolated from multiple tissues including adipose
tissue, skeletal muscle, synovium, spleen, thymus, blood, lung, fetal
blood, and amniotic fluid [8]. The most accessible and the best
characterized source of MSCs is the bone marrow although they are
found in relatively small numbers with an estimate of about 10 MSCs
for 1 million total bone marrow cells [9].
However, to the best of our knowledge, there is no report in the
medical literature regarding the efficacy of MSCs in the treatment of
asthma. The aim of the present study was to investigate the efficacy of
MSCs on lung histopathology in a murine model of asthma.2. Materials and methods
2.1. Experimental animals
Specific pathogen-free, 6- to 8-week-old, female BALB/c mice,
weighing 18 to 20 g, were maintained in the animal laboratory of
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in air-conditioned rooms and allowed ad libitum with food and
water on a 12-hour light/12-hour dark cycle. All experimental pro-
cedures were prepared according to the requirements of the Animal
Care and Ethics Committee of the Dokuz Eylul University. Thirty-six
BALB/c mice were divided into four groups; Group 1 (control group,
n=6), Group 2 (ovalbumin induced asthma only, n=10), Group 3
(ovalbumin induced asthma +MSC, n=10), and Group 4 (MSC only,
n=10).
2.2. Sensitization and inhalational exposure
BALB/c mice are high responders to ovalbumin [10]. Mice in
control groupwere not exposed to any intervention. Themice in study
Groups 2 and 3 were sensitized via two intraperitoneal injections, on
days 0 and 14 of the experiment, of 10 μg/0.1 ml chicken egg albumin
(ovalbumin, grade V, ≥98% pure; Sigma, St. Louis, MO, USA) with
alum as an adjuvant. After the sensitization, the mice in study Groups
2 and 3 were exposed to aerosolized ovalbumin for 30 min per day on
three days a week for eight weeks, beginning from the 21st day of the
study. The mice in control group were administered normal saline
with alum intraperitoneally on days 0 and 14 of the experiment and
exposed to aerosolized saline for 30 min per day on three days a week
for eight weeks, beginning from the 21st day of the study [11].
Exposures were carried out in a whole body inhalation exposure
system. Temperature and relative humidityweremaintained between
20–25 °C and 40–60%, respectively. A solution of 2.5% ovalbumin in
normal saline was delivered by aerosolization via compressed air to
a sidestream jet nebulizer injected into a chamber. The aerosol
generated by this nebulizer comprised N80% particles with a diameter
of b4 μm. Particle concentration was maintained in the range of 10 to
20 mg/mm3 [11].
2.3. Generation and administration of mesenchymal stem cells
2.3.1. Bone marrow harvest
In order to isolatemesenchymal stem cells, after sacrificing 6- to 8-
week-old BALB/c mice obtained from the Dokuz Eylul University,
femurs and tibias were dissected away from attached muscle and
connective tissue; the ends of the bones were removed. Bone marrow
was extruded by inserting a 21-gauge needle into the shaft of the
bone with cuts on both ends and flushing it with 1 ml of Dulbecco's
modified Eagle's medium (DMEM; Biological Industries, Israel)
supplemented with 10% fetal bovine serum (FBS). The marrow
plugs were dispersed by passage through a 16-gauge needle and the
marrowwas filtered through a 75-μm filter. Cells were plated in tissue
culture flask.
2.3.2. Isolation and culture of mesenchymal stem cells (MSCs)
Between 10 and 15×106 whole marrow cells were placed in a
75 cm2 tissue cultureflask inDMEMcontaining 15% fetal bovine serum
(FBS), 2 mmol/l L-glutamine, 100 U/ml of penicillin and 100 μg/ml
of streptomycin (Biological Industries, Israel) at 37 °C in a humidified
atmosphere of 5% carbon dioxide. After 72 h, the nonadherent
cells were removed by changing the medium. The medium was
completely replaced every 3 days and nonadherent cells were
discarded. Cultured MSCs were observed under inverted microscope
to assess the level of expansion and to verify the morphology at
each culture medium change. In order to prevent the MSCs from
differentiating or slowing their rate of division, each primary culture
was replaced (first passage) to 3 new flasks when the cell density
within colonies became 80–90% confluent, approximately 2 weeks
after seeding. The adherent cells were released from flasks with 0.25%
trypsin in 1 mmol/l sodium ethylenediaminetetraacetic acid (EDTA,
Sigma, St. Louis, MO, USA). After the twice-passaged cells becamenearly confluent, they were harvested and used for the experiments
[12].
2.3.3. Transfection of MSCs by GFP
In order to track stem cells in vivo, cells were transfected with
pEGFP-N1 Vector including GFP encoding gene (ClonTech, USA).
Lipid based transfection was performed with PolyFect Transfection
Reagent according to the kit instructions (Qiagen, USA). Briefly,
5×105 cells were plated and grown when they reach 60%
confluency. The day before transfection, MSCs grown in 75 cm2
flasks were detached by trypsin-EDTA treatment and replated into a
new sterile 75 cm2 flask at a density of 1.6×106 cells in 8 ml of
complete media. The cells were incubated at 37 °C and 5% CO2. The
next day, transfection mixture including 10 μg of plasmid DNA and
total volume was transferred drop wise onto the cells in the flasks.
The flask was gently swirled in an attempt to ensure uniform
distribution of the complexes. Finally, cells were incubated over-
night with the complexes and then were visualized under the
fluorescent microscope [12].
2.3.4. Flow cytometry
The cells were incubated with antibodies against CD45 PC5
(Beckman Coulter, Marsillia, France), NG2 PE (Beckman Coulter),
CD73 PE (Becton-Dickinson, Bioscience Pharmingen, San Diego, CA,
USA), and CD105 FITC (Serotec, Oxford, UK). Fluorescence histograms
were obtained by recording 20,000 cells/sample at a flow rate of
approximately 200 cell events/s. Experiments were conducted using
Coulter Epics XL-MCL and flow cytometric data were analyzed using
EXPO 32 ADC software (Beckman Coulter Inc, Miami, FL, USA) [13].
Flow cytometry analysis demonstrated that there were significant
expressions of MSC specific antigens (CD105, CD73, and NG2) and
absence of hematopoietic marker antigen (CD45).
2.4. MSC administration
Flow cytometry demonstrated that the cells were MSCs. Subse-
quently, 106 MSCs were administered via an insulin syringe from
the tail vein following OVA nebulization under superficial sedation to
each of the 10 mice in both Groups 3 and 4 (Fig. 1).
2.5. Histopathological analysis
Animals were sacrificed after two different time periods by an
overdose of ketamine after last MSC administration. First, half of the
animals were sacrificed at the end of one week in order to analyze
the histological findings of the lung tissue and whether MSCs
migrated to the inflamed lung tissue or not. Second, remaining mice
were sacrificed at the end of the second week in order to evaluate the
histopathological features of inflammation in the lungs. Two inves-
tigators who were blinded to the treatment groups interpreted the
histopathology. Tissue specimens were obtained from the mid zone of
the left lung of mice. Samples were fixed in 10% formalin for light
microscopic evaluation. Some tissue samples of 1 to 2 mm3 obtained
from adjacent regions were stocked in 2.5% glutaraldehyde for
electron microscopic evaluation. After fixation, samples were embed-
ded in paraffin for light microscopic evaluation and serial sections
of 5-μm thickness were prepared. After choosing the first section
randomly, 10 sections in each mouse were selected by skipping over
10 sections and proceeded to staining process. For light microscopic
evaluation, 3 different staining processes were used. The first 10
samples were stained with hematoxylin and eosin (H&E). In these
samples general tissue features were examined and thicknesses of
epithelium and subepithelial smooth muscle layers of the medium
and small airways were measured. In order to evaluate the
thicknesses of epithelium and subepithelial smooth muscle layers,
the measurements were performed from 4 points of each airway
0 75                      82        89
Nebulized OVA MSC or SF        Sacrifice
OVA (21TH-74TH, 3/weekly) given         
(0 and 14th day)
Healty mice  (group 1)
Asthma + SF (group2)
Asthma + MSC (group 3)
Healty mice+MSC (group4)
serum Lung 
tissue
Fig. 1. Time table for mouse model of airway inflammation and treatment with MSC.
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contained approximately 2 to 3 airways, nearly 20 or more airways
were evaluated for each mouse.
Photomicrographs were taken by JVC TK-890-E camera (Japan),
which was adapted on Olympus BH-2 RFCA model microscope
(Olympus Optical, Tokyo, Japan). The histological analysis was carried
out with UTHSCSA Image Tool for Windows Version 3.00 software.
The consecutive 10 sections were stained with toluidine blue and
the other 10 sections with periodic acid-Schiff (PAS). Photomicro-
graphs were taken randomly from 5 fields of each section that were
stained with toluidine blue. For mast cell enumeration, a standard
transparent counting frame representing an area of 16,400 μm2 was
used manually and 8 fields in each photograph were examined
for each mouse. Goblet cells stained with PAS were enumerated in
10 sections of each mouse. In each section, randomly selected 3 to
5 airways were photographed. Circumferences of all airways were
measured and goblet cell numbers in these areas were recorded. For
standardization, goblet cell numbers in 100 μm were analyzed by
dividing the total goblet cell number to the total length of airway
circumferences and multiplying the result by one hundred.
Tissues were embedded in EPON after follow-up process of
electron microscopic evaluation. Airways were marked from the
semithin sections by light microscope. Ultrathin sections were
obtained and stained with uranyl acetate and lead citrate. Libra 120
Carl Zeiss EFTEM electron microscope (Oberkochen, Germany) was
used for this evaluation. For eachmouse, 5 to 7 ultrathin sectionswere
achieved from each 2 blocks for evaluation of epithelium of the
airway, the surrounding structures, and the intercellular connections.
For each mouse, 8 to 10 areas were photographed by Trondle
(2048×2048 pixel) digital camera, attached to the electron micro-
scope. Thicknesses of the basement membrane of the respiratory
epithelium were measured from 20 points of preparations at equal
distances to each other and the data were recorded in sequence.
In order to analyze whether MSCs migrated to the lung tissue,
confocal microscopic evaluation was made by a blinded investigator.2.6. Measurements of serum NO levels
Serum NO level was measured with Griess method; 100 μl
serum sample was mixed with an equal volume of Griess reagent
(naphthyl ethylene-diamine dihydrochloride, % 0.15 mM; o-phos-
phoric acid in sulfanilamide % 1,5) in microtiter plates (Maxisorb
immunoplate, NUNC) and was stored at room temperature for ten
minutes [14].2.7. Statistical analysis
SPSS 11 package programwas used for the statistical analysis. Data
were presented as mean±standard deviation (SD) (minimum–
maximum). The comparisons between all groups were conducted
by using Kruskal–Wallis method. When differences were statistically
significant, Mann–Whitney U test was used for group comparisons.
Pb0.05 was considered statistically significant.
3. Results
Histopathologic results, serum NO levels and the migration of
MSCs to the lung tissue of thirty-six BALB/c mice divided into four
groups [Group 1 (control group, n=6), Group 2 (ovalbumin induced
asthma only, n=10), Group 3 (ovalbumin induced asthma + MSC,
n=10), and Group 4 (MSC only, n=10)] were evaluated.
Flow cytometry analysis demonstrated that there were significant
expressions of MSC specific antigens (CD105, CD73, and NG2) and
absence of hematopoietic marker antigen (CD45) (Fig. 2A–D).
In order to demonstrate the establishment of asthma model, we
compared control Group 1 (non asthmatic) with Group 2 (asthmatic,
placebo).
In the chronic asthmaGroup 2 (placebo), the numbers of mast cells
and goblet cells as well as the thickness of basement membrane,
epithelium, and subepithelial smooth muscle layer were significantly
higher when compared to the control group (Table 1). Besides, the
disrupted respiratory epithelium, perivascular and peribronchial
mononuclear cell infiltration (Fig. 3), increased number of degranu-
lated goblet cells in secretory phase, and secretory granules released
to lumen were demonstrated in microscopic images (Fig. 3). These
results demonstrated that the model was successfully established.
In the early phase of Group 3; the thickness of basement mem-
brane and subepithelial smooth muscle layer as well as the number of
mast and goblet cells were significantly smaller than the early phase
of Group 2 (Table 2, Fig. 3) (Pb0.05).
In the late phase of Group 3; the thickness of basement membrane,
epithelium, and subepithelial smooth muscle layer as well as the
number of mast and goblet cells were significantly smaller than the
late phase of Group 2 (Table 2, Fig. 3) (Pb0.05).
While mice in Group 4 did not have significant MSC in their lungs,
all mice in Group 3 were shown to have green dots indicating labeled
MSC that migrated to the inflamed lung tissues under confocal
microscope (Fig. 4).
In both early and late phases, serum NO levels in Group 3, were
significantly lower than Group 2 (Fig. 5).
Fig. 2. The results of flow cytometric analysis indicating that the cells were MSCs since CD105, CD73, and NG2 were positive and CD45 negative.
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Airway inflammation in asthma causes subsequent structural
changes called as remodeling [15]. The structural changes inTable 1
Comparison between control (Group 1) and asthma groups.
Control
(mean±SD)
Asthma
(mean±SD)
P
Basement membrane thickness (nm) 262.61±16.40 651.55±12.32 0.00
Subepithelial smooth muscle thickness
(μm)
3.49±0.42 9.26±1.14 0.00
Epithelium thickness (μm) 12.30±1.41 32.26±6.08 0.00
Numbers of goblet cells/100 (μm) 0.30±0.12 2.51±0.29 0.00
Numbers of mast cells/16,400 (μm2) 0.71±0.12 2.91±0.47 0.002asthmatic airways arise as a result of an injury/repair process.
Currently, drugs used for the treatment of asthma have a little effect
on airway remodeling [16]. Thus we aimed to investigate the efficacy
of MSCs especially on remodeling in murine model of chronic asthma.
The differentiation of MSCs into osteoblasts, chondroblasts,
adipocytes, and hematopoietic supporting stroma is a well-known
knowledge. In the recent reports MSCs also differentiate into non
stromal tissues, including lung epithelial cells. In fact, the differenti-
ation of MSCs into airway and lung parenchyma epithelial cells was
shown in in vitro and in vivo experiments [17]. After producing the
respiratory cell types from stem cells, the derivation of stem cells
might be used for lung replacement/regeneration therapeutics. It is
well known that MSCs can migrate to the areas of inflammation [18].
In our study, we showed that MSCs migrated to lung tissue in Group 3
with confocal microscopy.
Fig. 3. Light and electron microscopic findings of control (C), placebo (asthma) (P), MSC-early (E) and MSC-late (L) groups. In representative histological images, lung tissues were
stained with H&E (1st row; C1 (100×), P1 (100×), E1 (40×) and L1 (40×)), PAS (2nd row (40×); C2, P2, E2 and L2) and toluidine blue (3rd row (100×); C3, P3, E3 and L3). Note the
increased peribronchiolar mononuclear infiltration (*) and thickened subepithelial smooth muscle (arrow with 2 heads) in OVA-induced asthma mice (P1) compared to normal
tissue (C1). Av; Airway. High numbers of goblet cells (arrowheads) were seen with PAS-staining (P2), and mast cells with toluidine blue staining (P3). MSC suppressed goblet cell
hyperplasia in lung tissue. Electron microscopic findings (4th row) revealed a thickened basement membrane (*) and smooth muscle cells (Sm) in group placebo (P4, 1000×).
Healthy respiratory epithelium with cilia (C) and goblet cells (Gc) in groups C (1600×), E (1000×) and L (1000×).
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MSCs in the treatment of lung diseases [19,20]. For example, it is
suggested that the MSCs might be used to restore the abnormal CFTR
function in the cystic fibrosis that was caused by mutations of cystic
fibrosis transmembrane conductance regulator [21]. Since, there was
no enough study about the effect of MSCs on the asthma therapy we
decided to investigate the effect of MSCs on the asthma therapy in
chronic asthma model of the mice.
In the different studies, human and mouse stem cells can be
produced in order to express the markers of airway or alveolar
epithelial phenotype in vitro [22]. In some of these studies, it has beenTable 2
Comparison between study groups.
Asthma
(n: 10)
Early
(n: 5)
Late
(n: 5)
Basement membrane thickness (nm) 651.55±12.32 654.30±1
Subepithelial smooth muscle thickness (μm) 9.26±1.14 9.75±0
Epithelium thickness (μm) 32.26±6.08 30.35±1
Numbers of goblet cells/100 (μm) 2.51±0.29 2.41±0
Numbers of mast cells/16,400 (μm2) 2.91±0.47 3.09±0
⁎ Comparison of the groups regarding early phase results.
# Comparison of the groups regarding late phase results.shown that bone marrow progenitor cells can help in repairing and
remodeling of the lung in a rat model of progressive pulmonary
hypertension [23]. MSCs could take a more relevant role in lung
modulating of local inflammatory and immune responses. Recently,
Gazdhar et al. had a study that they derived MSCs accelerating
alveolar epithelial repair in vitro [24]. Moreover Lane et al. thought
that differentiated embryonic stem cells, particularly enriched for a
specific phenotype have a potential role in cell therapy for lung
diseases [25]. In our study, we observed that MSCs helped repairing
the inflammation of the lung tissue with the histopathological
examination.MSC + asthma
(n:10)
P* P#
Early
(n: 5)
Late
(n: 5)
0.65 507.06±10.02* 333.47±15.51# 0.00 0.00
.91 6.40±0.24* 5.07±0.52# 0.047 0.00
.50 24.94±1.67 16.16±0.51# 0.059 0.002
.22 1.31±0.26* 1.04±0.17# 0.010 0.045
.40 1.51±0.27* 1.48±0.49# 0.039 0.002
Fig. 4. A) Confocal microscopic appearance of lung tissue of a mouse in Group 3 (stem cell treated asthma group) showing that MSC migrated to the lung; B) Confocal microscopic
appearance of lung section of a mouse in Group 4 showing that no labeled-MSC was present (40×; green dots represent nanocrystals of celltrackers indicating MSCs (arrow)).
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could decrease lung injury. Four hours after the intratracheal
endotoxin administration, application of intratracheal MSCs de-
creased mortality, pulmonary edema, and levels of TNFa and MIP-1b
in the bronchoalveolar lavage (BAL) fluid when compared to only-
endotoxin treated mice [26]. MSCs change into bronchial or alveolar
epithelium. When systemic administration of MSCs is compared with
intratracheal administration of MSCs to the mice with bleomycin-
injured lungs, systemic administration of MSCs reduced the levels of
pro-inflammatory cytokines and levels of matrix metalloproteinases 2
and 9 in the lungs [27,28]. These results showed that MSCs might
have significant immunomodulatory effects in the lung. MSCs are also
used to modulate airways inflammation in CF. However, these studies
are not resulted in any routine therapeutic strategies. In our study,
BAL examination could not be done for the evaluation of inflamma-
tory cytokines (IL-4 and IL-5) because of the large numbers of the
erythrocytes in the specimens.
Although MSCs are beneficial on the lung regeneration and repair,
there is also evidence that they can cause or help in the development
of parenchymal fibrosis. Hashimoto et al. showed that utilization of a
bleomycin model in lung fibrosis up to 80% of the collagen-producing
fibroblasts in the lung was found to be bone marrow-derived [29]Fig. 5. A) The comparison of serum NO levels in the early phase between Groups 2 and 3while Epperly et al. showed that administration of intravenous MSCs
following lung irradiation contributed to migration of fibroblasts
and myofibroblasts in areas of damage [30]. Circulating fibrocytes
migrate to the injured lung tissue as a result of bleomycin challenge
for collagen deposition. The effect of administration of anti-CXCL12
antibodies causes reduction in fibrotic response [31]. The most
concerning issue about the characteristics of stem cell is unlimited
self-renewal of the cells, potential of change into malignancy [32].
There is some evidence that these cells develop karyotype abnormal-
ities during in vitro culture [33]. In addition, it was demonstrated
that MSCs in a murine model have been associated with sarcoma
development within the lung parenchyma [34,35]. The addition of
MSCs to human breast carcinoma cells in a mouse subcutaneous
xenograft model led to an increased rate of metastasis. MSCs helped
the de novo secretion of CCL5 from the cells acting in a paracrine
fashion resulting in increased motility and invasion of the malignant
cells [36]. This influence is reversible and dependent on continued
CCL5 secretion. The reason of dividing groups into early and late
phases is to observe the possible adverse effect of the MSCs, but we
did not observe any adverse effect in histopathological examination.
The fact that NO levels are increased in the exhaled breath
condensate of patients with asthma serves as a non-invasive means of. B) The comparison of serum NO levels in the late phase between Groups 2 and 3.
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in asthmatics were reported to be due to the release of NOS II enzyme
in the airways and normalization of NO levels was demonstrated after
steroid therapy [38]. Moon et al. demonstrated that production of
inducible NO in lung tissue after OVA challenge of mice was inhibited
by curcumin and they also demonstrated that supplementation with
curcumin in human epithelial cells decreased iNOS and NO production
induced by IFN-γ [39]. In our study we could not study NO levels in
exhaled breath because of the absence of condensator. However, we
could study NO levels in serum with Griess method. The results of NO
levels in serum indicated that MSCs were effective on decreasing NO
levels. NO levels in serum can also be an indicator of inflammation
in asthmatic airways. It could be hypothesized that the alterations
of NO levels may lay behind the antiasthmatic effect of MSC as also
shown in our study.
There were some limitations of our study such as cytokine levels
could not be evaluated and the results found in our study may not be
translated to positive findings in human clinical trials. In this study, in
order to determine the effects of MSCs in the treatment of chronic
asthma, we evaluated only histological changes and serum NO levels.
Most of the asthma models are devoid of the chronic histopathologic
changes seen in human asthma because of short-term exposure to
inhaled antigen. Temelkovski et al. suggested that this experimental
model replicated many features of human asthma [10]. Although we
could only evaluate the histological changes of asthma, the validity of
our method increases the value of our study.
Our results pointed to the ameliorating effects of MSCs on the
chronic changes in the airways of asthmaticmice. Further studies with
long-term treatments, which evaluate the effects of MSCs on lung
inflammation and remodeling, are needed.
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